Annals of Oncology Q1 Unclaimed

Elsevier Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Annals of Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 229. It is an CC BY Journal with a Single blind Peer Review review system The scope of the journal is focused on Cancer, Oncology, Systemic anticancer therapy, Molecular pathology. It has an SJR impact factor of 1,039 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright: CC BY

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

- €

Gold OA

-

Green OA

- €

Non OA

Metrics

Annals of Oncology

1,039

SJR Impact factor

229

H Index

1047

Total Docs (Last Year)

8249

Total Docs (3 years)

9316

Total Refs

15748

Total Cites (3 years)

7777

Citable Docs (3 years)

1,85

Cites/Doc (2 years)

8,9

Ref/Doc

Aims and Scope


Cancer Oncology Systemic anticancer therapy Molecular pathology


Best articles

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

View more

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

View more

A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267

View more

A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients

View more

Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

View more

An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP

View more

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma

View more

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

View more

Are liquid biopsies a surrogate for tissue EGFR testing?

View more

Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer

View more

Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial

View more

Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome

View more
SHOW MORE ARTICLES

BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection

View more

BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease

View more

Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial

View more

Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma

View more

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer

View more

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?

View more

Coming into focus: the nonovarian origins of ovarian cancer

View more

Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009

View more

Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma

View more

Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer

View more

Crossover is not associated with faster trial accrual

View more

Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'

View more

Comments

No comments ... Be the first to comment!